Table 1.
Clinical characteristics of the different CIBISa trials
| CIBIS | CIBIS II | CIBIS III | |
|---|---|---|---|
| n | 641 | 2647 | 1010 |
| Age, years (mean) | 59 | 61 | 72 |
| Female | 17% | 19% | 32% |
| NYHA class III/IV | 95%/5% | 83%/17% | 50%/0% |
| Ischemic heart failure | 55% | 50% | 62% |
| Idiopathic dilated cardiomyopathy | 36% | 12% | 10% |
| ACEI | 90% | 96% | – |
| Diuretics | 100% | 99% | 90% |
| Heart rate, bpm | 83 ± 1.5 | 81 ± 15 | 79 ± 13 |
| Systolic blood pressure, mmHg | 126 | 130 ± 19 | 134 ± 17 |
| Diastolic blood pressure, mmHg | 78 | 80 ± 11 | 80 ± 10 |
| LVEF (%) | 25 ± 0.9 | 27 ± 6 | 28.8 ± 5 |
| Mean dose bisoprolol, mg | 3.8 ± 0.2 |
a
for CIBIS, quantitative results are presented as mean ± SEM.
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; CIBIS, Cardiac Insufficiency Bisoprolol Studies; LVEF, left ventricular ejection fraction.